Mesoblast (MESO) reported late Thursday that sales of its steroid-refractory acute graft-versus-host disease treatment, Ryoncil, totaled $36 million in fiscal Q4.
For the year ended June 30, Ryoncil revenue was $115 million.
The company expects continued revenue growth in fiscal 2027, said CEO Silviu Itescu.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments